29th Jun 2021 07:00
Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ - Tuesday, June 29, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) announces the following blocklisting six monthly return:
1. | Name of applicant:
| HUTCHMED (China) Limited
| ||
2. | Name of scheme:
| (a) | Share Option Scheme conditionally adopted by HUTCHMED in 2005 ("2005 HUTCHMED Share Option Scheme")
| |
(b) | Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")
| |||
(c) | Warrant instrument granted by HUTCHMED on June 25, 2020 ("Warrant")
| |||
3. | Period of return:
| From December 29, 2020 to June 28, 2021
| ||
4. | Balance under scheme from previous return:
| (a) | 2005 HUTCHMED Share Option Scheme: 1,338,910 ordinary shares of US$0.1 each
| |
(b) | 2015 HUTCHMED Share Option Scheme: 53,271,648 ordinary shares of US$0.1 each
| |||
(c) | Warrant: 16,666,670 ordinary shares of US$0.1 each
| |||
5. | The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
| (a) | 2005 HUTCHMED Share Option Scheme: Nil
| |
(b) | 2015 HUTCHMED Share Option Scheme: Nil
| |||
(c) | Warrant: Nil
| |||
6. | Number of securities issued/allotted under scheme during period:
| (a) | 2005 HUTCHMED Share Option Scheme: 400,000
| |
(b) | 2015 HUTCHMED Share Option Scheme: Nil
| |||
(c) | Warrant: Nil
| |||
7. | Balance under scheme not yet issued/allotted at end of the period:
| (a) | 2005 HUTCHMED Share Option Scheme: 938,910 ordinary shares of US$0.1 each
| |
(b) | 2015 HUTCHMED Share Option Scheme: 53,271,648 ordinary shares of US$0.1 each
| |||
(c) | Warrant: 16,666,670 ordinary shares of US$0.1 each
| |||
8. | Number and class of securities originally listed and the date of admission:
| 25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) | ||
9. | Total number of securities in issue at the end of the period:
| 744,515,660 ordinary shares of US$0.1 each | ||
Name of contact:
| Christian Hogg | |||
Address of contact:
| Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
| |||
Telephone number of contact: | +852 2121 8200 | |||
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries | |
Mark Lee, Senior Vice President | +852 2121 8200 |
Annie Cheng, Vice President | +1 (973) 567 3786 |
Media Enquiries | |
Americas - Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) [email protected] |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)[email protected] |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) |
Nominated Advisor | |
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |
Related Shares:
Hutchmed